Skip to main content


From foundational patents to delivery technology, we have pioneered the development of mRNA medicine since our founding. Along the way, we have accumulated a broad collection of patents, with several hundred additional pending patent applications. 

Intellectual Property

The following articles are protected by the following United States patents for Moderna Inc.

Spikevax™ (mRNA-1273 COVID-19 VACCINE)

US 11,622,972

US 11,524,023

US 11,485,972

US 10,898,574

US 10,703,789

US 10,702,600

US 10,577,403

US 10,442,756

US 10,266,485

US 10,064,959

US 9,868,692

In addition, Moderna Inc. owns additional patents in the United States and foreign jurisdictions.